title: [Intolerance to hydroxychloroquine marketed in Spain (Dolquine) in patients with autoimmune conditions].
abstract: BACKGROUND
  A significant proportion of our patients has described to have problems from tolerance to Dolquine, a new presentation of hydroxychloroquine recently marketed in Spain, compared to Plaquenil. The objective was to know the tolerability and the adverse effects of this new presentation.
  
  
  METHODS
  A cross-sectional multicenter study on 133 patients treated with Dolquine was conducted.
  
  
  RESULTS
  Of the 133 patients (87% women; average age [AA]: 32.9 [15.4] years) who received Dolquine during an average period of 6.7 (1.4) months, 32 patients (24%) described to have more problems with this drug in comparison with other antimalarial. The adverse effects experienced were: bitter taste (62.4%), difficulty in swallowing the tablet (13.5%), dyspepsia (9.8%), nausea (7.5%), vomiting (1.5%), pruritus (1.5%), diarrhea (0.7%), and instability feeling (0.7%). The presence of gastrointestinal adverse effects was not related to the consumption of gastroerosive drugs, gastric protectors, or a high number of drugs. The attrition rate was 9.8%. Conclusions. Dolquine induces lower tolerance and more gastrointestinal adverse effects than Plaquenil, pointing out its bitter taste and the difficulty in swallowing it. Despite this higher intolerance there was not an increase in the attition rate from the antimalarial treatment in comparison to other series.
authors.affiliation: Unidad de Enfermedades Autoinmunes Sistémicas, Hospital Universitario Virgen de las Nieves, Facultad de Medicina, Granada. jfrancisco.jimenez.sspa@juntadeandalucia.es
authors.forename: J
authors.initials: J
authors.lastname: Jiménez-Alonso
authors.forename: J M
authors.initials: JM
authors.lastname: Sabio
authors.forename: P L
authors.initials: PL
authors.lastname: Carrillo-Alascio
authors.forename: J
authors.initials: J
authors.lastname: Jiménez-Jáimez
authors.forename: N
authors.initials: N
authors.lastname: Ortego-Centeno
authors.forename: E
authors.initials: E
authors.lastname: Jiménez-Jáimez
authors.forename: C
authors.initials: C
authors.lastname: Hidalgo-Tenorio
authors.forename: M
authors.initials: M
authors.lastname: Guzmán-Ubeda
authors.forename: L
authors.initials: L
authors.lastname: Jáimez
authors.forename: R
authors.initials: R
authors.lastname: Cáliz
authors.forename: A
authors.initials: A
authors.lastname: García-Sánchez
authors.forename: M
authors.initials: M
authors.lastname: Gallego
authors.forename: L
authors.initials: L
authors.lastname: Caminal
authors.forename: J L
authors.initials: JL
authors.lastname: Callejas-Rubio
authors.forename: R
authors.initials: R
authors.lastname: Cervera
authors.forename: J
authors.initials: J
authors.lastname: Font
mesh_terms: D000328:Adult; D000329:Advertising; D000962:Antimalarials / Q000009:adverse effects* / Q000627:therapeutic use; D001327:Autoimmune Diseases / Q000276:immunology; D005260:Female; D006801:Humans; D006886:Hydroxychloroquine / Q000009:adverse effects* / Q000627:therapeutic use; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000276:immunology*; D008297:Male; D013030:Spain
chemical_list: D000962:Antimalarials; D006886:Hydroxychloroquine